Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluation

Swaak, AJG; van den Brink, HG; Smeenk, RJT; Manger, K; Kalden, JR; Tosi, S; Domljan, Z; Rozman, B; Logar, D; Pokorny, G; Kovacs, L; Kovacs, A; Vlachoyiannopoulos, PG; Moutsopoulos, HM; Chwalinska-Sadowska, H; Kiss, E; Cikes, N; Anic, B; Schneider, M; Fischer, R; Bombardieri, S; Mosca, M; Graninger, W; Smolen, JS

dc.contributor.author	Swaak, AJG	en
dc.contributor.author	van den Brink, HG	en
dc.contributor.author	Smeenk, RJT	en
dc.contributor.author	Manger, K	en
dc.contributor.author	Kalden, JR	en
dc.contributor.author	Tosi, S	en
dc.contributor.author	Domljan, Z	en
dc.contributor.author	Rozman, B	en
dc.contributor.author	Logar, D	en
dc.contributor.author	Pokorny, G	en
dc.contributor.author	Kovacs, L	en
dc.contributor.author	Kovacs, A	en
dc.contributor.author	Vlachoyiannopoulos, PG	en
dc.contributor.author	Moutsopoulos, HM	en
dc.contributor.author	Chwalinska-Sadowska, H	en
dc.contributor.author	Kiss, E	en
dc.contributor.author	Cikes, N	en
dc.contributor.author	Anic, B	en
dc.contributor.author	Schneider, M	en
dc.contributor.author	Fischer, R	en
dc.contributor.author	Bombardieri, S	en
dc.contributor.author	Mosca, M	en
dc.contributor.author	Graninger, W	en
dc.contributor.author	Smolen, JS	en
dc.date.accessioned	2014-03-01T01:51:21Z
dc.date.available	2014-03-01T01:51:21Z
dc.date.issued	2001	en
dc.identifier.issn	0961-2033	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/26271
dc.subject	SLE	en
dc.subject	disease activity	en
dc.subject	SLEDAI	en
dc.subject	ECLAM	en
dc.subject	damage index	en
dc.subject.classification	Rheumatology	en
dc.subject.other	RHEUMATOLOGY DAMAGE INDEX	en
dc.subject.other	CLINICAL-FEATURES	en
dc.subject.other	SURVIVAL	en
dc.subject.other	RELIABILITY	en
dc.subject.other	VALIDATION	en
dc.subject.other	VARIABLES	en
dc.subject.other	SLEDAI	en
dc.title	Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluation	en
heal.type	journalArticle	en
heal.language	English	en
heal.publicationDate	2001	en
heal.abstract	Data related to the disease course of patients with systemic lupus erythematosus (SLE) with special attention to the persistence of disease activity in the long term are scarce. Al this moment reliable figures are only known about the survival rate as a measure of outcome. The aim of this multicenter study was to describe the outcome of SLE patients with a disease duration of greater than 10y. Outcome parameters were two disease activity-scoring systems (SLEDAI and ECLAM), the end organ damage (SLICC/ACR damage index) and treatment. Our results are derived from 187 SLE patients followed at 10 different centres in Europe over a period of ly. Serious clinical signs pr exacerbations, defined by the occurrence or detoriation of already existing symptoms of renal and cerebral nervous systems were observed in 2-11% of the patients, seizures and psychosis in 3%, proteinuria in 11% and an increase in serum creatinine in 5% of the patients. No change took place in the overall damage index. Yet, the disease course in most patients was characterized by periods of tiredness (42-60%), arthritis (20-25%), skin involvement such as malar rash (32-40%), migraine (15-20%), anaemia (15%) and leucopenia (17-19%). Summarizing these results it is shown that patients, still under care after such a long time of having this disease, do have a disease that is far from extinguished.	en
heal.publisher	ARNOLD, HODDER HEADLINE PLC	en
heal.journalName	LUPUS	en
dc.identifier.isi	ISI:000168235100008	en
dc.identifier.volume	10	en
dc.identifier.issue	1	en
dc.identifier.spage	51	en
dc.identifier.epage	58	en